Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel antibiotics to treat the serious and life-threatening multidrug-resistant infections that pose a major and growing global health threat. Tetraphase’s proprietary breakthrough chemistry technology enables the design of molecules that can overcome antibiotic resistance. Our drug platform has led to the creation of more than 3,000 broad- and selective-spectrum antibiotic drug candidates. Tetraphase common stock trades under the NASDAQ symbol ‘TTPH.’ Tetraphase is well positioned to be a major player in the multidrug-resistant arena.
Company Growth (employees)
Watertown, US
Size (employees)
69 (est)
Tetraphase Pharmaceuticals was founded in 2006 and is headquartered in Watertown, US

Key People at Tetraphase Pharmaceuticals

Patrick Gage

Patrick Gage


Tetraphase Pharmaceuticals Office Locations

Tetraphase Pharmaceuticals has an office in Watertown
Watertown, US (HQ)
110 480 Arsenal St

Tetraphase Pharmaceuticals Metrics

Tetraphase Pharmaceuticals Financial Metrics

Revenue (2016)

$5.1 m

Revenue growth (2015-16), %


Net income (2016)

($77.5 m)

Market capitalization (28-Apr-2017)

$293.9 m

Closing share price (28-Apr-2017)


Cash (31-Dec-2016)

$142.1 m
Tetraphase Pharmaceuticals's current market capitalization is $293.9 m.
Tetraphase Pharmaceuticals's revenue was reported to be $5.1 m in 2016 which is a 56% decrease from the previous period.
FY, 2013FY, 2014Y, 2015Y, 2016


$18.3 m$9.1 m$11.7 m$5.1 m

Revenue growth, %


Operating expense total

$131.1 m$74.9 m$94.7 m$83 m


($112.8 m)($65.8 m)($83 m)($77.8 m)

EBIT margin, %


Interest expense

$1.7 m$1 m$231 k$231 k

Interest income

$10 k$17 k$42 k$350 k

Net Income

($119.7 m)($66.7 m)($83.2 m)($77.5 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$102.7 m$121 m$205.9 m$142.1 m

Accounts Receivable

$1.7 m$3.5 m$4.2 m$1.8 m


$1 m$2.1 m$3.7 m$6.6 m

Current Assets

$105.4 m$126.6 m$213.8 m$150.5 m


$235 k$300 k$943 k$1.1 m

Total Assets

$105.9 m$127.2 m$214.9 m$151.7 m

Accounts Payable

$1.9 m$4.1 m$2.9 m$2.6 m

Current Liabilities

$13.2 m$17.3 m$10.7 m$11.5 m

Additional Paid-in Capital

$207.5 m$295 m$473.7 m$487.1 m

Retained Earnings

($186.5 m)($269.7 m)($347.1 m)

Total Equity

$87.8 m$108.6 m$204.1 m$140.1 m

Financial Leverage

1.2 x1.2 x1.1 x1.1 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($29.6 m)($66.7 m)($83.2 m)($77.5 m)

Depreciation and Amortization

$129 k$124 k$193 k$282 k

Accounts Receivable

$746 k($1.8 m)($693 k)$2.4 m


($154 k)($1.2 m)($1.5 m)

Accounts Payable

$310 k$2.2 m($1.2 m)($302 k)

Cash From Operating Activities

($24.5 m)($57.6 m)($76.7 m)($63.8 m)

Purchases of PP&E

($129 k)($191 k)($838 k)($393 k)

Cash From Investing Activities

($129 k)($191 k)($838 k)($393 k)

Cash From Financing Activities

$118.3 m$76.1 m$162.4 m$333 k

Interest Paid

$1.1 m$945 k$363 k$363 k

Tetraphase Pharmaceuticals Market Value History

Tetraphase Pharmaceuticals Online Presence

Tetraphase Pharmaceuticals Company Life

You may also be interested in